Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Published byVítězslav Říha Modified over 5 years ago

Similar presentations

Presentation on theme: "Clinical Outcomes and Prognosis of Recurrent Thymoma Management"— Presentation transcript:

1 Clinical Outcomes and Prognosis of Recurrent Thymoma Management
Mi Kyung Bae, MD, Chun Sung Byun, MD, Chang Young Lee, MD, Jin Gu Lee, MD, In Kyu Park, MD, PhD, Dae Joon Kim, MD, Woo Ick Yang, MD, PhD, Kyung Young Chung, MD  Journal of Thoracic Oncology  Volume 7, Issue 8, Pages (August 2012) DOI: /JTO.0b013e a91 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Diagram of the study. WHO, World Health Organization.
Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a91) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 The patterns of recurrence.
Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a91) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Median intervals from the initial resection to recurrence according to WHO histological type and Masaoka stage. WHO, World Health Organization. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a91) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Overall survival after recurrence of patients with recurrent thymoma. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a91) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Overall survival difference after recurrence according to the presence of myasthenia gravis (A), WHO histological type (B), Masaoka stage of the initial thymoma (C), interval from the initial resection to recurrence (D), pattern of recurrence (E), and completeness of re-resection (F). Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a91) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 Overall survival difference after the initial thymoma resection. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a91) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Clinical Outcomes and Prognosis of Recurrent Thymoma Management"

Similar presentations

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.
Blood lactate level during extracorporeal life support as a surrogate marker for survival  Sung Jun Park, MD, Sang-pil Kim, MD, PhD, Joon Bum Kim, MD,

Blood lactate level during extracorporeal life support as a surrogate marker for survival  Sung Jun Park, MD, Sang-pil Kim, MD, PhD, Joon Bum Kim, MD,
Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Efficacy of Polyglycolic Acid Sheet After Thoracoscopic Bullectomy for Spontaneous Pneumothorax  Seokkee Lee, MD, Seong Yong Park, MD, Mi Kyung Bae, MD,

Efficacy of Polyglycolic Acid Sheet After Thoracoscopic Bullectomy for Spontaneous Pneumothorax  Seokkee Lee, MD, Seong Yong Park, MD, Mi Kyung Bae, MD,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.

Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
E13-01: Insights into thymic epithelial tumor: pathology

E13-01: Insights into thymic epithelial tumor: pathology
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
P2-090: Expression of cellular retinol binding protein-1 is associated with poor prognosis of stage I non-small cell lung cancer  Moo Suk Park, Yoon Soo.

P2-090: Expression of cellular retinol binding protein-1 is associated with poor prognosis of stage I non-small cell lung cancer  Moo Suk Park, Yoon Soo.
Analysis of Unexpected Conversion to Thoracotomy During Thoracoscopic Lobectomy in Lung Cancer  Chun Sung Byun, MD, Sungsoo Lee, MD, PhD, Dae Joon Kim,

Analysis of Unexpected Conversion to Thoracotomy During Thoracoscopic Lobectomy in Lung Cancer  Chun Sung Byun, MD, Sungsoo Lee, MD, PhD, Dae Joon Kim,
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

Similar presentations

Ads by Google